CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN) today announced the presentation of initial clinical data from an ongoing Phase I study evaluating the Company’s huC242-DM4 compound for the treatment of colorectal, pancreatic, gastric and other CanAg-expressing cancers.
